Beijing Luzhu says Phase III trial shows LZ901 shingles vaccine efficacy at 91.6% in adults 40+

• Beijing Luzhu Biotechnology reported Phase III China results for its LZ901 shingles vaccine in Nature Communications on Aug. 7, 2026.
• The study showed strong protection against shingles in adults 40 and older, including reduced risk of key complications.
• Safety was broadly comparable to placebo for severe reactions, despite a higher rate of short-term side effects in the vaccine group.
• A China biologics license application filed in January 2025 remains under review, keeping commercialization timing tied to regulators.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beijing Luzhu Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260809-12277978), on August 09, 2026, and is solely responsible for the information contained therein.